Real-world data on LOKELMA for patients with hyperkalemia1

INDICATION AND LIMITATION OF USE

LOKELMA is indicated for the treatment of hyperkalemia in adults.

LOKELMA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.

K+ icon representing reduction in potassium level
LOKELMA Prescription Badge

In a real-world evidence study:

Patients with CKD on short-term LOKELMA therapy had higher rates of HK-related hospitalizations or ED visits than those on long-term LOKELMA therapy1

In a retrospective matched cohort study of closed US medical and pharmacy claims between January 2019 – December 2022

Rates of HK-related inpatient admissions or ED visits by LOKELMA duration in CKD or ESKD* population (N=2854 matched† pairs)1

Bar chart showing higher HK-related admission rates with short-term LOKELMA (1.27) vs long-term (0.76)

HK-related hospitalizations or ED visits do not necessarily imply HK as the primary reason for hospitalizations or ED visits.

Mean (SD) duration of1:

  • Study follow-up: 134 (57.3) days and 172 (23.8) days
  • LOKELMA use‡: 21 (11.4) days and 167 (52.4) days

In the short-term and long-term LOKELMA cohorts, respectively.

*CKD defined by diagnosis code and ESKD by either diagnosis code for ESKD, Stage 5 CKD, or unspecified ESKD.1

†Patients were propensity score matched based on the duration of LOKELMA therapy and were followed for 6 months after index date or until they were censored.1

‡Duration of LOKELMA use was the sum days of supply for all LOKELMA prescriptions during the follow-up period starting from index date to censoring date or date of LOKELMA discontinuation.1

KEY LIMITATIONS: Visibility into patient persistence was limited in insurance claims data by automated prescription refills and there was no confirmation of the actual amount of medication taken. Although the study matched for baseline variables found in health insurance claims database, unmeasured confounding is likely to exist due to the observational study design and absence of lab results. Causality cannot be inferred.1

GALVANIZE was a retrospective, matched cohort study of closed US medical and pharmacy claims evaluating HK-related hospitalizations or ED visits in adult outpatients who initiated LOKELMA (index date) between January 2019 and December 2022. Patients were propensity score matched based on the duration of LOKELMA therapy and were followed for 6 months after index date or until they were censored (re-initiated LOKELMA after ≥30-day gap of discontinuation, initiated another K+ binder, at the end of data availability, or death). Closed and adjudicated claims ensured a prior authorization process to verify a documented serum K+ >5.0 mEq/L or HK diagnosis before dispensing LOKELMA.2

CHOOSE LOKELMA for rapid and sustained reductions in serum K+ levels

REVIEW THE SAFETY PROFILE FOR LOKELMA